Updated Results from a Multicenter, Phase 2 Study of Acalabrutinib, Venetoclax, Obinutuzumab (AVO) in a Population of Previously Untreated Patients with CLL Enriched for High-Risk DiseaseChristine E. Ryan, Matthew S. Davids, Yue Ren et al.|Blood|2022Cited by 23
Mutations Detected in Real World Clinical Sequencing during BTK Inhibitor Treatment in CLLJennifer R. Brown, Matthew S. Davids, Kiyomi Mashima et al.|Research Square|2024Cited by 13